BMS, Ono Sue Amgen Over Opdivo Biosimilar Ahead of FDA Decision
Bristol Myers Squibb and Ono Pharmaceutical are challenging Amgen's proposed Opdivo biosimilar through a lawsuit, alleging patent infringement. The legal action comes as the FDA's decision on the…












